Brian O Mahony/X
Apr 24, 2026, 14:29
Brian O Mahony: Switching, Bleeding, Surgery, And Washout For Emicizumab And Rebalancing Agents
Brian O Mahony, CEO of Irish Haemophilia Society, former President of WFH and EHC, shared a post on X:
”Young WFH Congress 2026.
Table illustrating switching,bleed management,surgical management and washout periods for Emicizumab and the 3 rebalancing agents.”
Other posts featuring Brian O Mahony on Hemostasis Today.
-
Apr 24, 2026, 14:10Abel Sandmann։ How Common Are Cerebral Cavernous Malformations, Actually?
-
Apr 24, 2026, 13:43Mahesan Subramaniam: Raspberry Support Heart, Brain, and Metabolic Health
-
Apr 24, 2026, 13:34Joakim Nordanstig: SWEDEPAD Data Show Early Risk Of Limb Loss With Paclitaxel-Coated Devices
-
Apr 24, 2026, 13:18Lukas Jeker։ Making Genomic Medicine Affordable for More Patients
-
Apr 24, 2026, 11:27Caterina Casari: Thank You WFH for a Great Congress
-
Apr 24, 2026, 11:15Megan Adediran: A Moment to Pause, Learn, and Be Renewed
-
Apr 24, 2026, 11:09Veronica Sanchez: AHA Warns Most Women and Girls May Face Cardiovascular Disease by 2050
-
Apr 24, 2026, 09:38Luis Ferreira Moita: Rethinking Sepsis Care Through the Lancet Commission Initiative
-
Apr 24, 2026, 09:33Emmanuele Kouvousis: Do Calcium Supplements Increase the Risk of CVD Recurrence?